Acumen Pharmaceuticals Inc.

10/31/2024 | Press release | Distributed by Public on 10/31/2024 06:40

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual[...]